Overview

ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With Renal Cell Carcinoma (RCC)

Status:
Completed
Trial end date:
2020-05-11
Target enrollment:
Participant gender:
Summary
Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic RCC
Phase:
Phase 2
Details
Lead Sponsor:
Calithera Biosciences, Inc
Treatments:
Everolimus
Sirolimus